Philips to Launch Locally-Manufactured Advanced Molecular Imaging System in China, Strengthening Localization Strategy through Strategic Investment in Sinounion

Editor's Note: This article is reprinted fromPR Newswire, republished by VCBeat with authorization.

● Philips announces the launch of a China-made advanced molecular imaging system in the Chinese market in the second quarter of this year, further enriching its “localized” product portfolio in China.

● Philips (China) made a strategic investment in Syno United and partnered with the company to provide advanced molecular imaging systems for the Chinese market.

● Philips has established a comprehensive end-to-end value chain in China, spanning R&D, manufacturing, market channels, sales, and services, while collaborating with the “local ecosystem” to accelerate its “localization” process.

Royal Philips Announces Launch of Locally Produced Advanced Molecular Imaging System in the Chinese Market in Q2 This Year. In recent years, in the field of precision diagnosis, Philips has achieved local R&D and manufacturing of certain products such as ultrasound, CT, and MR in the Chinese market. By integrating advanced informatics and intelligent systems, and focusing on the clinical needs of local customers, Philips provides integrated localized solutions. The localization of the advanced molecular imaging system further enriches Philips’ “localized” product portfolio in the Chinese market.

To better serve the Chinese market, Philips is collaborating with the local ecosystem to foster full supply chain localization in China. Philips (China) Investment Co., Ltd. also announced a strategic investment in Syno United Medical Technology (Beijing) Co., Ltd. to strengthen their long-term strategic partnership. Philips will work with Syno United to provide advanced molecular imaging systems tailored for the Chinese market.

He Guowei, Member of the Philips Global Executive Committee and President of Greater China, stated: “China is Philips’ second-largest market globally. Philips is comprehensively advancing its ‘localization’ strategy in China by building a complete ‘end-to-end’ value chain that covers all aspects, including R&D, manufacturing, marketing channels, sales, and services, to better serve the Chinese market with greater speed, more precise insights, and optimized approaches. While strengthening our local innovation and manufacturing capabilities, we collaborate with leading local innovative enterprises and integrate internal and external resources to create the best possible experience for local customers. This is an integral part of Philips’ implementation of its ‘localization’ strategy in China.”

Wang Tao, founder of Sinounited Medical Technology (Beijing) Co., Ltd., stated, “Sinounited is committed to building a full industrial chain in the fields of precision oncology diagnosis and treatment and nuclear medicine. We have successively launched multiple high-end large-scale molecular imaging equipment with complete independent intellectual property rights, as well as several world-first innovative clinical application technologies. By achieving independent research, development, and manufacturing, we aim to realize domestic substitution in the field of high-end medical equipment and address critical bottlenecks in the industry. Our strategic cooperation with Philips aims to integrate the century-long innovation heritage and global perspective of an international enterprise with the rapid and excellent innovation and manufacturing capabilities of local Chinese companies. Together, we will co-create competitive localized solutions in the field of nuclear medicine and jointly promote the development of nuclear medicine in China to a higher level.”

Driven by the “Healthy China 2030” initiative, China is emerging as one of the world’s largest health technology markets. The Chinese government is deepening healthcare system reforms with the primary goals of reducing care costs and improving public well-being, while encouraging innovation in health technologies. Advanced molecular imaging serves as a critical tool for precise early screening and diagnosis in oncology, cardiology, neurology, and other specialties. Under the 14th Five-Year Plan, nuclear medicine has been elevated to the level of national strategy, with the “one nuclear medicine department per county” initiative formally incorporated into the plan. The demand for nuclear medicine in China is substantial, offering broad prospects for growth. Philips is committed to embedding itself within China’s local health technology ecosystem, supporting the local healthcare system in achieving four key objectives: improving population health, enhancing patient experience, increasing healthcare professional satisfaction, and reducing care costs.

Royal Philips is a leading health technology company dedicated to improving people’s health and well-being, and enabling better outcomes across the healthcare continuum—from healthy living and prevention, to diagnosis, treatment and home care. Leveraging advanced technology, rich clinical experience, and deep consumer insights, Philips continuously introduces integrated innovative solutions. The company holds leadership positions in the fields of diagnostic imaging, image-guided therapy, patient monitoring, health informatics, and consumer health and home care. Headquartered in the Netherlands, Philips generated EUR 17.2 billion in sales in 2021, employs approximately 78,000 people worldwide, and maintains sales and service operations in more than 100 countries. For more information, please visit the Philips global website:www.philips.com; or the Philips China website:www.philips.com.cn。

SinoUnited Medical Technology (Beijing) Co., Ltd. is a manufacturer of high-end medical equipment and an innovative service provider. Guided by its core value proposition of “Deliver · Witness,” the company is rooted in scientific research and committed to quality, dedicating itself to the widespread adoption of advanced medical equipment and the enhancement of healthcare service quality. With domestically produced PET/CT molecular imaging products as its cornerstone, SinoUnited has strategically laid out an integrated industry chain for precision diagnosis and treatment in nuclear medicine, driving the development of application scenarios for medical devices, medical data, and artificial intelligence. Headquartered in Zhongguancun, Beijing, the company has launched multiple PET/CT systems with fully independent intellectual property rights, achieving domestic substitution for high-end PET/CT scanners and earning recognition from numerous healthcare institutions and industry experts. Meanwhile, SinoUnited has achieved global firsts in several key technologies, including “Free Breathing” and “Passive Quality Control,” breaking technological monopolies and leading industry innovation. For more information, please visit the official website of SinoUnited:www.sinounion.com。